It’s not yet clear whether the pharmaceutical industry’s male fountain of youth – widely used billion dollar testosterone treatments – is in jeopardy of collapsing following an advisory panel’s near unanimous recommendations that the drugs’ indication be significantly narrowed and cardiovascular outcomes studies be conducted.
In fact a handful of advisors told the agency they didn’t think a label change would have much affect at...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?